Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT03273322

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03273322
Other papers using this trial's data
  • Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study Circulation. Cardiovascular interventions, 2020-07 DOI, PubMed 32674675

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03273322. Randomized; no masking; primary purpose treatment. Start 2017-09-13 (actual); primary completion 2018-11-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
Acronym
ADRIFT
Condition
Atrial Appendage
Condition
Hemorrhage
Intervention (Drug)
Rivaroxaban 10 mg qd
Intervention (Drug)
Rivaroxaban 15 mg qd
Intervention (Drug)
DAPT
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Action Research Group (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct03273322
Content hash
d1bc60eceb235ce87cb6b08189ab173fbef7e932961ec8f8d7d6d9ddd7ce8269